Presentation and Status in Health Basket
| Presentation | Basket | Yarpa | Pharmasoft |
|---|---|---|---|
|
Film Coated Tablets 30 X 5 mg |
|
13466 | 26189 |
|
Film Coated Tablets 60 X 7.5 mg |
|
13488 | 26190 |
|
Film Coated Tablets 30 X 10 mg |
|
13487 | 26188 |
|
Orodispersible Tablets 30 X 5 mg (ZAPPA ODT) |
|
47259 | 26184 |
|
Orodispersible Tablets 30 X 10 mg (ZAPPA ODT) |
|
47262 | 26185 |
Related information
Dosage
Initial, maintenance: 10 mg daily.
Adjust in range: 5-20 mg dailly.
Method of administration: Zappa 5 and Zappa 10: If necessary, the tablet can be halved for immediate use. There is no information about crushing or chewing the tablet. Swallow the medicine with a little water.
Zappa 7.5: Do not halve the tablet. There is no information about crushing or chewing the tablet. Swallow the tablet with a little water.
See prescribing information for full details.
Indications
Schizophrenia: Acute monotherapy: Treatment of acute mixed or manic episodes associated with Bipolar I Disorder.
Preventing recurrence in bipolar disorder: In patients whose manic episodes have responded to olanzapine treatment, therapy is indicated for the prevention of recurrence in patients with Bipolar Disorder.
Contra-Indications
Known hypersensitivity to the product.
Risk of narrow-angle glaucoma-type (increased intraocular pressure) eye problems.
Special Precautions
Neuroleptic malignant syndrome has been reported in association with administration of antipsychotic drugs, including olanzapine.
Tardive dyskinesia, potentially irreversible, may develop in patients treated with antipsychotic drugs. Should be prescribed in a manner that is most likely to minimize the occurence of tardive dyskinesia.
May induce orthostatic hypotension.
Patients with known cardiovascular disease (history of myocardial infarction or ischemia, heart failure, or conduction abnormalities), cerebrovascular disease, and conditions which would predispose patients to hypotension.
Should be used cautiously in patients with a history of seizures or with conditions that potentially lower the seizure threshold.
As with other drugs that antagonize dopamine D2 receptors, olanzapine elevates prolactin levels, and a modest elevation persists during chronic administration.
The possibility of suicide attempt is inherent in schizophrenia and in bipolar disorder, and close supervision of high-risk patients should accompany drug therapy.
See prescribing information for full details.
Side Effects
Schizophrenia: Postular hypotension, constipation, weight gain, dizziness, personality disorder, akathisia.
Bipolar mania: Asthenia, dry mouth, constipation, dyspepsia, increased appetite, somnolence, dizziness, tremor.
See prescribing information for full details.
Drug interactions
Alcohol, CNS depressants, cimetidine, disulfiram, carbamazepine, levodopa.
See prescribing information for full details.
Pregnancy and Lactation
Pregnancy: Neonates may develop withdrawal syndrome if the mother has taken the medicine during the last trimester (the last three months) of pregnancy. The withdrawal syndrome includes the following symptoms: restlessness, tremor, muscle stiffness/weakness, sleepiness, nervousness,
respiratory and feeding problems.
Lactation: This medicine is not for use during lactation.